PHL-GEMFIBROZIL 600 MG
GEMFIBROZIL : 600 MG · DIN 02254867 · PHARMEL INC
Health Canada status: CANCELLED POST MARKET
What is PHL-GEMFIBROZIL?
PHL-GEMFIBROZIL 600 MG contains GEMFIBROZIL : 600 MG. It is listed in the Health Canada Drug Product Database under DIN 02254867, held by PHARMEL INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 05-Apr-2013. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PHL-GEMFIBROZIL used for?
Adjunct to diet for: very high serum triglycerides (Type IV/V hyperlipidemia) at risk of pancreatitis; hypercholesterolemia and Type IIa/IIb mixed dyslipidemias to regulate lipid levels.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02254867 |
|---|---|
| Brand name | PHL-GEMFIBROZIL |
| Generic / active ingredient | GEMFIBROZIL : 600 MG |
| Manufacturer | PHARMEL INC |
| Strength | 600 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AB04 GEMFIBROZIL |
| AHFS class | 84:80.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 05-Apr-2013 |
| Original market date | 2005-02-22 00:00:00 |
How is it administered?
Recommended adult dose: 1200 mg daily in two divided doses (600 mg twice daily) 30 minutes before morning and evening meals. Maximum dose: 1500 mg/day.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store in a dry place at between 15°C and 30°C.
How is it supplied?
300 mg Capsules: HDPE bottles of 100, 250, and 500. 600 mg Tablets: HDPE bottles of 100, 250, and 500.
Contraindications
Hepatic/renal dysfunction; gallbladder disease; hypersensitivity; pregnancy/lactation; Type I hyperlipoproteinemia; concomitant use with repaglinide.
Warnings and precautions
Risk of severe myopathy and rhabdomyolysis, especially with HMG-CoA reductase inhibitors; potential for cholelithiasis (gallstones); liver tumor risk based on animal studies.
What can be used instead?
Other Canadian products sharing ATC code C10AB04 GEMFIBROZIL. 1 of 22 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| TEVA-GEMFIBROZIL | 600 MG | TABLET | TEVA CANADA LIMITED | MARKETED | DIN 02142074 |
| APO-GEMFIBROZIL | 600 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 01979582 |
| APO-GEMFIBROZIL CAP 300MG USP | 300 MG | CAPSULE | APOTEX INC | CANCELLED POST MARKET | DIN 01979574 |
| DOM-GEMFIBROZIL | 300 MG | CAPSULE | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02241608 |
| DOM-GEMFIBROZIL | 600 MG | TABLET | DOMINION PHARMACAL | CANCELLED POST MARKET | DIN 02230580 |
| GEMFIBROZIL CAP 300MG | 300 MG | CAPSULE | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00851922 |
| GEMFIBROZIL TAB 600MG | 600 MG | TABLET | OMNI LABORATORIES DIVISION, WARNER-LAMBERT CANADA INC. | CANCELLED POST MARKET | DIN 00851930 |
| GEMFIBROZIL-300 - CAP | 300 MG | CAPSULE | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02136031 |
| GEMFIBROZIL-600 - TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 02136058 |
| LOPID 600MG | 600 MG | TABLET | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 00659606 |
Who else supplies GEMFIBROZIL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. GEMFIBROZIL appears in 24 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.